LOGO
LOGO

Clinical Trial Calendar

Results Date
Company Name
Ticker
Event
Indication
Outcome
Autumn 2025
Assembly Biosciences, Inc.
ASMB
Interim data from Phase 1b trial of ABI-5366
Recurrent genital herpes
Autumn 2025
Arcus Biosciences, Inc
RCUS
Overall survival data from Phase 2 trial of domvanalimab plus zimberelimab and chemotherapy (EDGE-Gastric)
Upper gastrointestinal adenocarcinomas
Autumn 2025
Assembly Biosciences, Inc.
ASMB
Interim efficacy, safety and pharmacokinetic data from Phase 1b trial of ABI-1179
Recurrent genital herpes
Autumn 2025
Wave Life Sciences Ltd.
WVE
Data from complete 400 mg single dose cohort of Phase 1b/2a trial of WVE-006 (RestorAATion-2)
Alpha-1 antitrypsin deficiency (AATD)
Autumn 2025
Alkermes plc
ALKS
Topline data from Phase 2 trial of ALKS 2680 (Vibrance-2)
Narcolepsy type 2
Positive topline results reported on Nov. 12, 2025
Q4 2025
TuHURA Biosciences Inc.
HURA
Data from Phase 1b/2a trial of IFx-Hu2.0 in combination with pembrolizumab
Non-cutaneous metastatic Merkel cell carcinoma (MCC)
Q4 2025
C4 Therapeutics, Inc.
CCCC
Data from Phase 1 dose escalation study of cemsidomide
Non-Hodgkin’s lymphomas (NHL)
Q4 2025
Avidity Biosciences, Inc
RNA
Topline and functional data from Phase 2 trial of Delpacibart zotadirsen (EXPLORE44-OLE)
Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44)
Positive topline and functional data reported on Nov 19, 2025
Q4 2025
Avidity Biosciences, Inc
RNA
Long-term 4 mg/kg and safety data from Phase 2 trial of Delpacibart etedesiran (MARINA-OLE)
Myotonic dystrophy type 1 (DM1)
Q4 2025
Celcuity Inc.
CELC
Topline data readout from PIK3CA mutant cohort of the Phase 3 trial of gedatolisib in combination with fulvestrant with and without palbociclib (VIKTORIA-1)
HR+, HER2- advanced breast cancer
Q4 2025
Inhibrx Biosciences, Inc.
INBX
Initial data from Phase 2 trial of INBRX-106 in combination with KEYTRUDA
Head and neck squamous cell carcinoma
Q4 2025
Inhibrx Biosciences, Inc.
INBX
Interim data from the Phase 1/2 trial of INBRX-106
Refractory or relapsed non-small cell lung cancer
Q4 2025
PureTech Health plc
PRTC.L
Topline data from Phase 1b trial of LYT-200 as monotherapy and in combination with venetoclax/HMA
Hematological malignancies and solid tumors
Q4 2025
Benitec Biopharma
BNTC
Interim Results from Cohort 1 of Phase 1b/2a trial of BB-301
Oculopharyngeal Muscular Dystrophy (OPMD)
Q4 2025
CervoMed Inc.
CRVO
Initial safety, biomarker and pharmacokinetic data from Phase 2b trial of Neflamapimod (RewinD-LB)
Mild-to-moderate Dementia with Lewy Bodies
Q4 2025
Adverum Biotechnologies Inc.
ADVM
Two-year long-term follow-up data from Phase 2 trial of Ixo-vec (LUNA)
Wet age-related macular degeneration
Q4 2025
Palatin Technologies Inc.
PTN
Topline results from Phase 3 trial of PL9643 (MELODY-2)
Dry eye disease
Q4 2025
Palatin Technologies Inc.
PTN
Topline results from Phase 3 trial of PL9643 (MELODY-3)
Dry eye disease
Q4 2025
Alector Inc.
ALEC
Top-line data readout from phase 3 trial of latozinemab (INFRONT-3)
Frontotemporal dementia with a granulin gene mutation (FTD-GRN)
The Phase 3 INFRONT-3 trial of latozinemab in individuals with frontotemporal dementia due to a progranulin gene mutation did not meet the clinical co-primary endpoint of slowing FTD-GRN progression. As a result, the continuation study for latozinemab will be discontinued. The data reported on 21st Oct. 2025
Q4 2025
FibroGen Inc.
FGEN
Topline results from Phase 2 trial of FG-3246 in combination with enzalutamide
Metastatic castration-resistant prostate cancer (mCRPC)
Q4 2025
Nektar Therapeutics
NKTR
Topline data from Phase 2b trial of Rezpegaldesleukin (REZPEG/NKTR-358)
Alopecia Areata
Q4 2025
Candel Therapeutics, Inc.
CADL
Biomarker and initial survival data from Phase 1b trial of CAN-3110
Recurrent High-Grade Glioma (rHGG)
Q4 2025
Capricor Therapeutics, Inc.
CAPR
Top-line Phase 3 data of CAP-1002 (HOPE-3)
Duchenne Muscular Dystrophy (DMD)
Positive topline results reported from its Phase 3 HOPE-3 trial of Deramiocel for the treatment of Duchenne muscular dystrophy on 3rd Dec, 2025
Q4 2025
AnaptysBio, Inc.
ANAB
Top-line 12 Week data from Phase 2 trial of rosnilimab
Moderate-to-severe ulcerative colitis
Phase 2 trial of rosnilimab did not meet primary or secondary endpoints at week 12 in Moderate-to-Severe Ulcerative Colitis, according to the company. The data reported on 10th Nov. 2025.
Q4 2025
Black Diamond Therapeutics
BDTX
Initial data from Phase 2 trial of BDTX-1535 (Silevertinib)
Newly diagnosed patients with non-classical epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC)
Topline data reported from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor receptor (EGFR) mutations (NCMs) on 3rd Dec. 2025.
Buy this Content
Editors Pick
trump 19122025 lt

ByteDance Signs Deal For TikTok's New US JV To Avoid Ban

December 19, 2025 01:16 ET
spacex 10122025 lt

SpaceX Boosts Plans For 2026 IPO, With Upto $1.5 Trln Valuation: Reports

December 10, 2025 09:07 ET
amazon 10122025 lt

Amazon Plans $35 Bln Investment In India By 2030 To Boost AI Innovation

December 10, 2025 04:37 ET
trumpwarnsnetflix 08122025 lt

Trump Warns Netflix-Warner Bros. Deal 'could Be A Problem'

December 08, 2025 05:34 ET
Copyright © 2025 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap